Skip to content
Clinical Trials – home

dr hab.n.med. Sławomir Mandziuk Specjalistyczna Praktyka Lekarska

Research site

Poland Chodzki 17/2, 20-093 Lublin, Poland

  • Non-small cell lung cancer · Small cell lung cancer
  • Adult patients

About Specializations

dr hab.n.med. Sławomir Mandziuk Specjalistyczna Praktyka Lekarska in Lublin, Poland specialises in clinical trials of conditions such as Non-small cell lung cancer, Small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms (Cancer Research)

The research program at dr hab.n.med. Sławomir Mandziuk Specjalistyczna Praktyka Lekarska is dedicated to Neoplasms with a focus on lung cancer, investigating both Previously Untreated Metastatic Non‑Small Cell Lung Cancer and Small Cell Lung Cancer. Ongoing studies aim to test new therapeutic regimens and assess biosimilar equivalence, seeking to improve patient outcomes.

  • Evaluation of lurbinectedin alone or with irinotecan in relapsed small‑cell lung cancer
  • Comparison of biosimilar CT-P51 with Keytruda in metastatic lung cancer

Located in Lublin, Poland, the centre has conducted two trials with a single investigator, reflecting a focused approach to advancing cancer treatment.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Chodzki 17/220-093 LublinPoland
Recruiting now
no trials
Conditions studied
2

More sites in LublinPoland

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Condition
Type of trial
Recruitment status
Quick filters

2 clinical trials

Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Celltrion Inc.

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Pharma Mar S.A.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.